| abstract |
The present disclosure encompasses the use of a CD86 antagonist binding domain and a CD40 antagonist, such as an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, Specific fusion protein consisting of different binding domains. Multi-specific fusion proteins may also include intervening domains that separate other domains. The present disclosure also provides polynucleotides encoding multi-specific fusion proteins, compositions of such fusion proteins, and methods of using multi-specific fusion proteins and compositions. |